By the GCCVest Team — GCCVest Insights Series
Summary generated with AI assistance and reviewed for accuracy
At GCCVest, we believe transformative innovation increasingly emerges from a connected world. The next generation of category-defining companies will not be built within the boundaries of a single geography, but at the intersection of exceptional science, entrepreneurial talent and patient, long-term capital.
Our investment in Epicrispr Biotechnologies (Epic Bio) reflects that conviction. We participated in the company’s Series B financing, led by Ally Bridge Group, drawn by a combination of groundbreaking science, world-class leadership — and a capital chain that runs straight down the corridor this firm was built to serve.
A New Frontier in Genetic Medicine
For much of the past decade, the promise of genetic medicine has been associated with the ability to edit DNA directly. Epicrispr is pursuing a different and potentially transformative approach.
The company is pioneering programmable epigenetic therapies designed to regulate gene expression without permanently altering the underlying genetic code. Rather than rewriting DNA, its technology seeks to control how genes are turned on or off — creating the potential for new therapeutic approaches across a broad range of diseases, with a reversibility profile that permanent editing cannot offer.
Epicrispr’s lead program targets facioscapulohumeral muscular dystrophy (FSHD), a serious genetic disease for which patients have historically had limited treatment options. The company’s progress in advancing its clinical program reinforced our confidence in both the platform and the team’s ability to execute.
The Corridor in Action
One reason Epicrispr resonated with us is that it shows, in a single cap table, how scientific innovation actually travels today.
The science is American: the company’s foundations originate in leading U.S. research institutions and the pioneering work of Dr. Stanley Qi, the Chinese-born Stanford scientist whose contributions to CRISPR-based gene regulation helped define the field of epigenetic engineering. But look at the capital that carried that science forward, and the chain runs link by link through Hong Kong — the node where GCCVest itself connects Gulf capital to Asian innovation.
Early backing came from Horizons Ventures, the Hong Kong investment firm backed by Li Ka-shing, whose portfolio spans many of the most influential technology and healthcare companies of the past two decades. The Series B in which we participated was led by Ally Bridge Group, the Hong Kong–headquartered firm founded by Frank Yu that has become one of Asia’s most respected healthcare investors. And our own participation brought Middle Eastern–backed capital, deployed through Hong Kong, into the same syndicate.
That is not a coincidence of geography. It is the corridor we have described throughout this Insights series — Asian networks and Gulf capital meeting around globally significant assets — operating in its most advanced form: not in infrastructure or manufacturing, but at the frontier of genetic medicine.
Since our investment, the company’s subsequent financing has drawn a distinguished group of healthcare and institutional investors including Octagon Capital, Janus Henderson Investors, Cormorant Asset Management, Sanofi Ventures, Fidelity Investments, Duquesne Family Office, Angelini Ventures and abrdn — extending the register from Asia and the Gulf to North America and Europe. The future leaders of biotechnology will be built this way: scientific excellence combined with long-term investors well beyond any single geography.
Why This Matters for the Middle East
The Gulf is undergoing a profound transformation. Across the region, governments, institutions and family offices are increasing their investments in healthcare, biotechnology, genomics and advanced research as part of building knowledge-based economies. While Epicrispr is headquartered in the United States and focused on global markets, the themes underlying its mission — precision medicine, genetic research, advanced therapeutics for diseases with significant unmet need — sit squarely within those ambitions.
We believe Gulf investors can play an important role in supporting these innovations: not merely as providers of capital, but as long-term partners helping connect scientific breakthroughs with global opportunity.
Deep science is where that partnership matters most. As we noted in our analysis of the World Intellectual Property Organization’s Global Innovation Index 2026, more than 30,000 deep-science startups have been founded worldwide since 2000, now worth some US$7.6 trillion — and half of them hold patents precisely because years separate invention from first revenue. Companies like Epicrispr are the definition of that category: ventures whose binding constraint is not ideas but capital with patience — and patience is the one resource the Gulf’s long-horizon investors hold in greater depth than anyone. The strength of Epicrispr’s shareholder base — experienced healthcare specialists alongside long-term-oriented capital — is what lets a clinical-stage platform build toward transformational outcomes on the timeline the science actually requires. The company’s continued momentum since our participation is, to us, validation of exactly that model.
Looking Ahead
At GCCVest, we seek opportunities where exceptional founders, differentiated technology and long-term capital come together. Epicrispr embodies all three — and just as importantly, it illustrates the thesis at the heart of this firm: that some of the most compelling opportunities emerge where Asian networks, American research excellence and Middle Eastern capital converge.
As Gulf investors deepen their participation in life sciences, we believe companies like Epicrispr demonstrate the role global partnerships can play in advancing technologies with the potential to improve millions of lives. We are proud to count Epicrispr in our portfolio, and we look forward to following the next stage of its journey.
GCCVest Partners is a Hong Kong–based, Middle Eastern–backed cross-border asset management firm investing in Asian champions emerging as global leaders while using MENA as a strategic hub for internationalisation. GCCVest’s investment in Epicrispr Biotechnologies was made through GCCVest Healthtech 24 Ltd. Nothing in this article constitutes investment advice or an offer of securities. For a conversation on the Asia–MENA corridor, please contact our team at info@gccvest.com or visit gccvest.com.